Blockchain Registration Transaction Record

BenevolentAI Advances Novel Ulcerative Colitis Treatment in Phase 1a Trial

BenevolentAI's Dr. Anne Phelan shares positive safety data from the Phase 1a clinical study of BEN-8744, a potential treatment for ulcerative colitis. The study successfully met its objectives, proving the hypothesis that peripheral restriction could eliminate adverse side effects. Phelan detailed the study's methodology and highlighted BenevolentAI's innovative platform that integrates diverse data types through advanced AI and machine learning models.

The development of BEN-8744 as a potential treatment for ulcerative colitis represents a significant step forward in addressing the condition. BenevolentAI's innovative approach, utilizing advanced AI and machine learning models, has the potential to revolutionize drug development, ultimately leading to safer and more effective treatments for patients.